STAT3 and non-small cell lung carcinoma: In order to clarify the role of bortezomib in the NSCLC, we first detected the functional status of STAT3, PI3K-AKT, NF-κB, MAPK-p38 and MAPK-ERK1/2 signaling pathways after treated with IC25 and IC50 of bortezomib in the 7 types of NSCLC cells.